Tsingke Biotech Participates in TIDES USA 2025, Demonstrates Full-Scale Oligonucleotide Synthesis Capabilities

Visitors were particularly impressed by Tsingke's automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company's ability to integrate reagents, instruments, and services into a unified platform drew significant attention from pharmaceutical and biotech partners. Visitors were particularly impressed by Tsingke's automation capabilities and flexible modular equipment designed to support high-purity,...

Visitors were particularly impressed by Tsingke's automation capabilities and flexible modular equipment designed to support high-purity, long-chain, and highly modified oligonucleotide synthesis. The company's ability to integrate reagents, instruments, and services into a unified platform drew significant attention from pharmaceutical and biotech partners.

Tsingke Biotech remains committed to empowering life sciences and therapeutic innovation by building a world-class platform for nucleic acid synthesis.

For inquiries or collaboration, please contact us at [email protected]

Visit: www.tsingke.com

Photo - https://mma.prnewswire.com/media/2703094/TidesUSA_Photo.jpg

View original content:https://www.prnewswire.co.uk/news-releases/tsingke-biotech-participates-in-tides-usa-2025-demonstrates-full-scale-oligonucleotide-synthesis-capabilities-302473977.html